Details of the Drug Combination

General Information of Drug Combination (ID: DC9NWQQ)

Drug Combination Name
Azelnidipine Perindopril
Indication
Disease Entry Status REF
Cerebral Small Vessel Diseases Phase 4 [1]
Component Drugs Azelnidipine   DMA12HL Perindopril   DMOPZDT
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Azelnidipine
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Azelnidipine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Indication(s) of Perindopril
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [3]
Perindopril Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Perindopril Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [7]
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Perindopril Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [8]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01819441) Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6367).
4 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
5 Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J. 2002 Sep;66(9):811-5. doi: 10.1253/circj.66.811.
6 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
7 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
8 Experience with perindopril in normal volunteers. Arch Mal Coeur Vaiss. 1989 May;82 Spec No 1:35-41.
9 The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther. 2009 Nov;47(11):686-94. doi: 10.5414/cpp47686.